IFNGR1 and neoplasm: The IFNγR signaling pathway represents an essential molecule in solid tumor immunotherapy.[38] It is markedly upregulated in the FAST‐treated groups (Figure S4A, Supporting Information), suggesting a connection between IFNγR and the anti‐tumor immune effects of FAST.